- Home
- ROIV vs GTLB Comparison
ROIV vs GTLB Comparison
Compare ROIV & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- GTLB
- Stock Information
- Founded
- ROIV 2014
- GTLB 2011
- Country
- ROIV United Kingdom
- GTLB United States
- Employees
- ROIV N/A
- GTLB N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- GTLB EDP Services
- Sector
- ROIV Health Care
- GTLB Technology
- Exchange
- ROIV Nasdaq
- GTLB Nasdaq
- Market Cap
- ROIV 8.4B
- GTLB 7.0B
- IPO Year
- ROIV N/A
- GTLB 2021
- Fundamental
- Price
- ROIV $10.76
- GTLB $53.36
- Analyst Decision
- ROIV Buy
- GTLB Strong Buy
- Analyst Count
- ROIV 4
- GTLB 23
- Target Price
- ROIV $17.50
- GTLB $71.22
- AVG Volume (30 Days)
- ROIV 5.9M
- GTLB 2.2M
- Earning Date
- ROIV 05-29-2025
- GTLB 06-02-2025
- Dividend Yield
- ROIV N/A
- GTLB N/A
- EPS Growth
- ROIV N/A
- GTLB N/A
- EPS
- ROIV N/A
- GTLB N/A
- Revenue
- ROIV $122,585,000.00
- GTLB $759,249,000.00
- Revenue This Year
- ROIV N/A
- GTLB $26.19
- Revenue Next Year
- ROIV N/A
- GTLB $21.91
- P/E Ratio
- ROIV N/A
- GTLB N/A
- Revenue Growth
- ROIV 140.04
- GTLB 30.93
- 52 Week Low
- ROIV $8.73
- GTLB $37.90
- 52 Week High
- ROIV $13.06
- GTLB $74.18
- Technical
- Relative Strength Index (RSI)
- ROIV 49.33
- GTLB 65.91
- Support Level
- ROIV $10.58
- GTLB $44.53
- Resistance Level
- ROIV $11.77
- GTLB $47.41
- Average True Range (ATR)
- ROIV 0.34
- GTLB 1.77
- MACD
- ROIV -0.05
- GTLB 1.13
- Stochastic Oscillator
- ROIV 15.13
- GTLB 97.59
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About GTLB GitLab Inc.
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.